SCHEDULE: Research Alliance Corp IV: Major Stakeholder Filing

Multiple Biotechnology Value Funds and Mark N. Lampert report a combined beneficial ownership of 6.4% in Research Alliance Corp IV Class A Ordinary Shares.

Summary

• Several Biotechnology Value Funds (BVF) and Mark N. Lampert have filed a Schedule 13G, indicating their beneficial ownership of Research Alliance Corp IV's Class A Ordinary Shares.
• The filing details the aggregate beneficial ownership of these entities, with Mark N. Lampert and associated entities holding a combined 6.4% of the outstanding Class A Ordinary Shares.
• The total number of shares beneficially owned by the group is 500,000, based on 7,775,000 shares outstanding as of July 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership without specific financial or operational performance indicators.

Positives

• Significant stake held by experienced biotechnology investment entities, potentially indicating confidence in the company's future.
• Clear disclosure of beneficial ownership, promoting transparency for investors.

Negatives

• The filing does not contain financial performance data or operational updates, limiting insight into the company's current health.
• The disclosure is primarily a reporting requirement and does not inherently signal positive or negative company performance.

Risks

• Concentration of ownership among a few entities could influence corporate governance or strategic decisions.
• The nature of the reporting entities (biotechnology funds) suggests a focus on speculative or developmental stage companies, which carry inherent risks.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or company guidance.

Industry Context

StockSavvy.ai notes that this filing pertains to a Schedule 13G, which is typically filed by passive investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. The involvement of Biotechnology Value Funds suggests a focus on the life sciences sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles.

Stakeholder Impact

• Shareholders gain clarity on the significant beneficial ownership held by Biotechnology Value Funds and Mark N. Lampert.
• The market receives information about a substantial stake, which could influence perceptions of the company's investor base.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in Research Alliance Corp IV.
• Further amendments to the Schedule 13G may be filed if ownership levels change significantly.

Key Dates

Keywords

Research Alliance Corp IV, Schedule 13G, Biotechnology Value Fund, Mark N. Lampert, Beneficial Ownership, Class A Ordinary Shares, SEC Filing, Cayman Islands